Safety and Effectiveness Study of the Zenflow Spring System - A Minimally Invasive Treatment for LUTS Associated With BPH

Study Identifier:
CLIN-0130
CT.gov Identifier:
NCT04987138
EudraCT Identifier:
N/A
EU Trial (CTIS) Number:
N/A
Study Contact Information:
N/A
Recruitment Complete

Considering participating in a START clinical trial?

Get Started

Study Summary

Evaluate the safety and effectiveness of the Zenflow Spring System in relieving LUTS associated with BPH.

Medical Condition
The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.
  • Prostate
  • Urinary tract
    • Phase
    The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
    (N/A)
    Sex
    Male
    Age
    45+ years
    Study Drug
  • Drug: Other: Roll-in Cohort
    • Read More
  • Drug: Active Comparator: Treatment Arm
  • Drug: Sham Comparator: Control Arm
  • Drug: Other: Crossover Cohort
    • Study Status
    Indicates the current recruitment status or the expanded access status
    Recruitment Complete

    Requirements information
    Inclusion criteria
    • 1. Subject is able and willing to comply with all the assessments of the study,
    • 2. Subject or subject's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form,
    • 3. ≥ 45 years of age,
    • 4. Baseline IPSS score ≥ 13; ≥ 1 in the IPSS voiding to storage sub-score ratio (IPSS-V/S),
    • 5. Prostate volume 25 - 80 cc by transrectal ultrasound (TRUS), measured within 120 days post study consent,
    • 6. Prostatic urethral length between 25 and 45 mm, as measured by cystoscopic pull-back,
    • 7. Failed, intolerant, or subject choice to not take a medication regimen for the treatment of LUTS.
    Exclusion criteria
    • 1. Obstructive intravesical median prostatic lobe as determined by ultrasound (i.e., more than 10 mm intravesical prostatic protrusion on sagittal mid-prostate plane via abdominal ultrasound),
    • 2. High bladder neck with the absence of lateral lobe encroachment indicating a high likelihood of primary bladder neck obstruction as determined by the Investigator,
    • 3. Urethral stricture, meatal stenosis, or bladder neck stricture - either current or recurrent,
    • 4. Anatomical anomalies that will not accommodate the Implant, as determined by cystoscopy (e.g., prostatic urethral length to height geometry),
    • 5. Requires indwelling catheter or intermittent catheterization to void,
    • 6. Baseline PSA \> 10 ng/mL or confirmed or suspected prostate cancer (Subjects with a PSA level above 2.5 ng/mL, or age specific, or local reference ranges should have prostate cancer excluded to the Investigator's satisfaction),
    • 7. One of the following baseline test results, taken from a single uroflowmetry reading:
    • 1. Urinary volume void ≤ 125mL (pre-bladder urinary volume of ≥ 150 mL required),
    • 2. Peak urinary flow rate (Qmax) of ≤ 5 ml/second or \> 15 mL/second,
    • 3. Post- void residual volume (PVR) \> 250 mL
    • 8. History of other diseases causing voiding dysfunction including urinary retention (e.g., uncontrolled diabetes, diagnosis of neurogenic bladder, Parkinson's disease, multiple sclerosis, etc.),
    • 9. Subjects with overactive bladder in the absence of benign prostatic obstruction,
    • 10. Acute urinary tract infection (UTI) or finding of asymptomatic bacteriuria (Note: subject can be enrolled if the UTI is treated and followed with a negative urine test result), or subjects with history of recurrent UTIs (defined as \> 3 UTIs in the past 12 months),
    • 11. Concomitant bladder stones,
    • 12. Previous pelvic irradiation or radical pelvic surgery,
    • 13. Previous prostate surgery, including: enucleation, resection, vaporization, thermotherapy, ablation, stenting or prostatic urethral lift,
    • 14. Chronic prostatitis, recurrent prostatitis, chronic pelvic pain syndrome (CPPS), or painful bladder syndrome within the past 12 months
    • 15. Known allergy to nickel,
    • 16. Life expectancy less than 60 months,
    • 17. Use of concomitant medications (e.g., anticholinergics, antispasmodics or tricyclic antidepressants) affecting bladder function,
    • 18. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (Note: low dose aspirin therapy (81 mg) is permitted),
    • 19. Taking 5-alpha-reductase inhibitors within 3 months of baseline evaluation,
    • 20. Taking one of the following within 2 weeks of baseline evaluation:
    • 1. alpha-blockers,
    • 2. imipramine,
    • 3. anticholinergics,
    • 4. cholinergic gonadotropin releasing hormonal analogues,
    • 5. Phosphodiesterase-5 Enzyme Inhibitors (Tadalafil) in doses for BPH,
    • 6. Beta-3 adrenergic receptor agonist (Mirabegron),
    • 21. Taking androgens, unless eugonadal state for at least 3 months or greater as documented by the Investigator,
    • 22. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:
    • 1. phenylephrine, or,
    • 2. pseudoephedrine,
    • 23. Future fertility concerns, or,
    • 24. In the Investigator's opinion, the subject has a physical, psychological, or medical impairment that might prevent study completion or would confound study results (including subject questionnaires).

    Clinical Study Information for Healthcare Providers

    By clicking the button below you will find in-depth information about this clinical trial, including study design, primary and secondary endpoints, and more. This information is intended for healthcare professionals seeking to review the scientific and operational aspects of the study.

    View Study Information

    Study Locations

    Location
    Investigator
    Status
    Condition(s) Treated at Site
    Location
    START Carolinas
    Myrtle Beach, SC, United States, 29572
    Investigator
    Neal Shore
    Status
    Recruitment Complete
    Condition(s) Treated at Site
    Prostate
    Urinary tract